KRBPQ — Kiromic Biopharma Balance Sheet
0.000.00%
- $0.00m
- $12.52m
Annual balance sheet for Kiromic Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 10.2 | 25.4 | 0.645 | 3.2 | 1.14 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | 0.016 | 0 | — | — |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 10.7 | 27.1 | 1.69 | 4.43 | 3.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.07 | 3.63 | 10.3 | 7.72 | 5.22 |
| Other Long Term Assets | |||||
| Total Assets | 12.8 | 30.7 | 12 | 12.2 | 8.54 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 1.47 | 3.41 | 13.3 | 20.4 | 20.9 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.47 | 3.41 | 17.7 | 21.3 | 21.1 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 11.4 | 27.3 | -5.77 | -9.12 | -12.6 |
| Total Liabilities & Shareholders' Equity | 12.8 | 30.7 | 12 | 12.2 | 8.54 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |